About ClinTrial Research
ClinTrial Research runs a network of clinical research sites. It partners with global sponsors on Phase I to IV trials. The sites cover more than ten specialties, among them cardiology, nephrology, ophthalmology and rheumatology. The company also connects patients with studies they may join.
Network headquarters is in the Research Triangle area of North Carolina. The company also lists locations in Florida, Illinois, South Carolina and Texas. Sam Searcy is chief executive officer. In December 2025 the company closed a growth equity round led by Tarsadia Investments.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | Oct 28, 2026 | $428,123of $500K target | 3 | $142K | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Nov 26, 2025 | Jan 5, 2026 | $5,000,001of $5.0M target | 1 | $5.0M | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, two offerings | $5,428,124 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by ClinTrial Research
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Dec 17, 2025 | Growth equity | Undisclosed | Tarsadia Investments (lead) | PR Newswire release ↗ |
Why Investors Backed ClinTrial Research
ClinTrial Research runs clinical research sites that carry out clinical trials for drug sponsors. Its network is based in the Research Triangle area of North Carolina. Tarsadia Investments led a growth equity round in the company in December 2025. The company's mission is to build a site network that speeds up trials and widens patient access.
The problem it targets
Searcy's case is that site networks face four pressures. More than 90% of physicians who join a trial never run a second one. Sites also face staffing shortages, more complex study protocols and rising drug development costs. Searcy argues that a network able to solve all four will become a lasting part of drug development.
What the product does
Studies run with board-certified investigators and centralized operations. ClinTrial Research offers sponsors direct access to the patients a protocol needs. The site has a Participate Now link for people who want to join a study. Its blog explains eligibility, informed consent and decentralized trials for would-be participants.
Progress so far
The company has built a leadership team beyond its chief executive officer. Jennifer Yevoli is chief legal officer, Wendy Tomlinson is chief operating officer, and Doug Strasnick is chief business officer. Robert Miranda is vice president of clinical operations, and Stephen Hong is director of commercial strategy. The leadership page also lists quality assurance and regulatory directors.
Who backs it
Tarsadia Investments led the round. The wire release describes Tarsadia as a multi-billion-dollar firm that invests in category-defining companies around the world. Rishi Reddy, managing director and head of venture and growth equity at Tarsadia, said ClinTrial Research stood out among the companies the firm evaluated. He said Tarsadia spent more than two years studying site networks. He added that both sides focus on bespoke AI-enabled technology platforms for the sector. Searcy said the cultural fit was immediate from the first meeting.
We wrote this summary from public statements by ClinTrial Research and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on ClinTrial Research's Form D filed Oct 28, 2026.
Earlier filings also listed Wendy Tomlinson (executive officer, last listed Jan 2026), Ron Creatore (executive officer, last listed Jan 2026) and Douglas Strasnick (executive officer, last listed Jan 2026).